4D Molecular Therapeutics, Inc. Proceeds from Stock Options Exercised
4D Molecular Therapeutics, Inc. (FDMT) reported Proceeds from Stock Options Exercised of $3.11 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-05-09
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2024-03-31 was $3.11M, a 119.84% increase year-over-year.
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2023-03-31 was $1.42M, a 61.83% increase year-over-year.
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2022-03-31 was $875.00K, a 783.84% increase year-over-year.
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2021-03-31 was $99.00K, a 1880.00% increase year-over-year.
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for fiscal 2020 was $857.00K, a 1042.67% increase from fiscal 2019.
- 4D Molecular Therapeutics, Inc. proceeds from stock options exercised for fiscal 2019 was $75.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|
| 2024-03-31 | $3.11M 10-Q · filed 2024-05-09 | |
| 2023-03-31 | $1.42M 10-Q · filed 2024-05-09 | |
| 2022-03-31 | $875.00K 10-Q · filed 2023-05-11 | |
| 2021-03-31 | $99.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $857.00K 10-K · filed 2021-03-25 | |
| 2020-03-31 | $5.00K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $75.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |